Stock NEULANDLAB NEULAND LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Neuland Laboratories Limited

Equities

NEULANDLAB

INE794A01010

Market Closed - Bombay S.E.
Other stock markets
 06:00:53 2024-07-12 am EDT 		5-day change 1st Jan Change
8,095 INR -0.05% Intraday chart for Neuland Laboratories Limited +4.24% +53.10%
Jul. 02 Neuland Laboratories Leases Part of Telangana Property for INR315 Million MT
May. 14 Transcript : Neuland Laboratories Limited, Q4 2024 Earnings Call, May 14, 2024

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.61 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NEULAND LABORATORIES LIMITED Stock Neuland Laboratories Limited
+53.10% 1.24B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
A+
NOVARTIS AG Stock Novartis AG
+17.90% 228B
B-
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NEULANDLAB Stock
  4. Ratings Neuland Laboratories Limited